CN107406493B - 具有改善的半衰期的经修饰的血管性血友病因子 - Google Patents

具有改善的半衰期的经修饰的血管性血友病因子 Download PDF

Info

Publication number
CN107406493B
CN107406493B CN201680014025.4A CN201680014025A CN107406493B CN 107406493 B CN107406493 B CN 107406493B CN 201680014025 A CN201680014025 A CN 201680014025A CN 107406493 B CN107406493 B CN 107406493B
Authority
CN
China
Prior art keywords
leu
val
cys
ser
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680014025.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN107406493A (zh
Inventor
M·莫塞斯
S·舒尔特
G·迪肯内特
U·卡琳娜
S·佩斯特尔
T·韦默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kangnobel Linnau Co Ltd
Original Assignee
Switzerland Jette Bellin Bioproducts Reorganization Equipment Jsc
CSL Behring Recombinant Facility AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Switzerland Jette Bellin Bioproducts Reorganization Equipment Jsc, CSL Behring Recombinant Facility AG filed Critical Switzerland Jette Bellin Bioproducts Reorganization Equipment Jsc
Publication of CN107406493A publication Critical patent/CN107406493A/zh
Application granted granted Critical
Publication of CN107406493B publication Critical patent/CN107406493B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201680014025.4A 2015-03-06 2016-03-04 具有改善的半衰期的经修饰的血管性血友病因子 Active CN107406493B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15158065 2015-03-06
EP15158065.1 2015-03-06
PCT/EP2016/054647 WO2016142288A1 (en) 2015-03-06 2016-03-04 Modified von willebrand factor having improved half-life

Publications (2)

Publication Number Publication Date
CN107406493A CN107406493A (zh) 2017-11-28
CN107406493B true CN107406493B (zh) 2021-08-13

Family

ID=52629450

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680014025.4A Active CN107406493B (zh) 2015-03-06 2016-03-04 具有改善的半衰期的经修饰的血管性血友病因子

Country Status (12)

Country Link
US (1) US11155601B2 (enExample)
EP (1) EP3265483B1 (enExample)
JP (1) JP2018510212A (enExample)
KR (1) KR20170125941A (enExample)
CN (1) CN107406493B (enExample)
AU (1) AU2016231327B2 (enExample)
BR (1) BR112017018468A2 (enExample)
CA (1) CA2978374A1 (enExample)
DK (1) DK3265483T3 (enExample)
ES (1) ES2772933T3 (enExample)
SG (1) SG11201706659WA (enExample)
WO (1) WO2016142288A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
FI3648788T5 (fi) 2017-07-07 2024-09-09 Takeda Pharmaceuticals Co Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
JP7326246B2 (ja) 2017-07-07 2023-08-15 武田薬品工業株式会社 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
US20220395560A1 (en) * 2019-02-01 2022-12-15 Takeda Pharmaceutical Company Limited METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF)
EA202192140A1 (ru) * 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
WO2021001522A1 (en) * 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
WO2021094344A1 (en) * 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102161692A (zh) * 2011-03-08 2011-08-24 中国人民解放军第三军医大学 改造的止血多肽及其运用
CN102648212A (zh) * 2009-11-13 2012-08-22 基立福疗法公司 包含冯维勒布兰德因子(vWF)的制剂及其相关制备方法、试剂盒和用途
WO2014173873A1 (en) * 2013-04-22 2014-10-30 Csl Behring Gmbh Complex
WO2014198699A2 (en) * 2013-06-12 2014-12-18 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
CN104302296A (zh) * 2012-05-08 2015-01-21 德国杰特贝林生物制品有限公司 用于治疗血友病a和/或冯维勒布兰德病的糖组合物

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
NZ249786A (en) 1992-04-10 1995-05-26 Sprintpak Pty Ltd Postage stamp - luminescent coating comprises coated regions and non-coated regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
PT1754718E (pt) 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2329768C (en) 1998-04-27 2008-06-10 Opperbas Holding B.V. Pharmaceutical composition comprising factor viii and neutral liposomes
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
US7615622B2 (en) 2001-01-12 2009-11-10 University Of Maryland, Baltimore Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
EP1421539B1 (en) 2001-06-14 2009-10-28 The Scripps Research Institute Stabilized factor viii with engineered disulfide bonds
EP2292273A3 (en) 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
US8586538B2 (en) 2002-04-29 2013-11-19 Stichting Sanquin Bloedvoorziening Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1596887B1 (en) 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii moiety conjugates
SI1624891T2 (sl) 2003-05-06 2013-09-30 Biogen Idec Hemophilia Inc. Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
DK2371856T3 (en) 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
AU2005322067B8 (en) 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
KR20080007226A (ko) 2005-04-14 2008-01-17 체에스엘 베링 게엠베하 증가된 안정성을 가진 변형된 응고 인자 ⅷ 및 이의 유도체
WO2007126808A1 (en) 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
MX2009007145A (es) 2006-12-27 2009-08-27 Nektar Therapeutics Al Corp Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
PL2167117T3 (pl) * 2007-06-13 2013-01-31 Csl Behring Gmbh Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi
BRPI0814220B8 (pt) 2007-07-11 2021-05-25 Novo Nordisk As purificação de fator viii usando uma resina multimodal ou de modo misto
AU2008323768A1 (en) 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
PT2349342T (pt) 2008-10-17 2018-10-26 Baxalta Inc Factores sanguíneos modificados que compreendem um baixo grau de polímero solúvel na água
US20110306551A1 (en) 2009-02-19 2011-12-15 Novo Nordisk A/S Modification of Factor VIII
ES2427627T3 (es) 2009-04-06 2013-10-31 Novo Nordisk A/S Entrega dirigida de proteínas de Factor VIII a plaquetas
WO2011101284A1 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii fusion protein
EP2536753B1 (en) 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
US9234192B2 (en) 2010-02-16 2016-01-12 Novo Nordisk A/S Conjugated proteins
WO2011131510A2 (en) 2010-04-21 2011-10-27 Novo Nordisk A/S Selective modification of proteins
JP2013532176A (ja) 2010-07-15 2013-08-15 ノヴォ ノルディスク アー／エス 安定化させた第ｖｉｉｉ因子バリアント
US20150080309A1 (en) 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102648212A (zh) * 2009-11-13 2012-08-22 基立福疗法公司 包含冯维勒布兰德因子(vWF)的制剂及其相关制备方法、试剂盒和用途
CN102161692A (zh) * 2011-03-08 2011-08-24 中国人民解放军第三军医大学 改造的止血多肽及其运用
CN104302296A (zh) * 2012-05-08 2015-01-21 德国杰特贝林生物制品有限公司 用于治疗血友病a和/或冯维勒布兰德病的糖组合物
WO2014173873A1 (en) * 2013-04-22 2014-10-30 Csl Behring Gmbh Complex
WO2014198699A2 (en) * 2013-06-12 2014-12-18 Novo Nordisk A/S Compounds suitable for treatment of haemophilia

Also Published As

Publication number Publication date
JP2018510212A (ja) 2018-04-12
SG11201706659WA (en) 2017-09-28
US20180051067A1 (en) 2018-02-22
KR20170125941A (ko) 2017-11-15
ES2772933T3 (es) 2020-07-08
US11155601B2 (en) 2021-10-26
BR112017018468A2 (pt) 2018-04-17
CN107406493A (zh) 2017-11-28
DK3265483T3 (da) 2020-03-02
WO2016142288A1 (en) 2016-09-15
AU2016231327B2 (en) 2018-08-09
HK1244292A1 (en) 2018-08-03
EP3265483B1 (en) 2019-12-11
CA2978374A1 (en) 2016-09-15
EP3265483A1 (en) 2018-01-10
AU2016231327A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
AU2016231327B2 (en) Modified von Willebrand factor having improved half-life
KR101648734B1 (ko) 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
EP2814502B1 (en) Von willebrand factor variants having improved factor viii binding affinity
JP6573989B2 (ja) 血友病を処置するための切断型フォン・ヴィルブランド因子ポリペプチド
US11890327B2 (en) Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
JP7252890B2 (ja) 血友病を処置するための切断型フォン・ヴィルブランド因子ポリペプチド
JP6704420B2 (ja) フォンヴィレブランド因子の半減期を改善するための化合物
HK1244292B (en) Modified von willebrand factor having improved half-life
HK1250625B (en) Truncated von willebrand factor polypeptides for treating hemophilia
FVIII A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models
HK40008359B (en) Truncated von willebrand factor polypeptides for treating hemophilia
HK40008359A (en) Truncated von willebrand factor polypeptides for treating hemophilia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200120

Address after: Swiss sound

Applicant after: KangNobel Linnau Co., Ltd.

Address before: Bern, Switzerland

Applicant before: Jeter Behring biological products reorganization Equipment Co., Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant